Skip to main content
Clinical Trials/EUCTR2020-001886-35-GB
EUCTR2020-001886-35-GB
Active, not recruiting
Phase 1

A clinical trial of nebulized surfactant for the Treatment of moderate to severe COVID-19 in adults - COVID-19 Surfactant Clinical Trial

niversity Hospital Southampton NHS Foundation Trust0 sites20 target enrollmentMay 11, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
COVID-19 infection in patients requiring endotrachael intubation
Sponsor
niversity Hospital Southampton NHS Foundation Trust
Enrollment
20
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 11, 2020
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
niversity Hospital Southampton NHS Foundation Trust

Eligibility Criteria

Inclusion Criteria

  • 1\.Age \=18 years old
  • 2\.Confirmed COVID\-19 positive by PCR
  • 3\.Within 24 hours of mechanical ventilation
  • 4\.Assent obtained from personnel (PerLR) or professional legal representative (ProfLR)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 10
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 10

Exclusion Criteria

  • 1\.Imminent expected death within 24 hours
  • 2\.Specific contraindications to surfactant administration (e.g. known allergy, pneumothorax, pulmonary haemorrhage)
  • 3\.Known or suspected pregnancy
  • 4\.Stage 4 severe chronic kidney disease or requiring dialysis (i.e., eGFR \< 30\)
  • 5\.Liver failure (Child\-Pugh Class C)
  • 6\.Anticipated transfer to another hospital, which is not a study site within 72 hours.
  • 7\.Current participation or participation in another study within the last month that in the opinion of the investigator would prevent enrollment for safety purposes.
  • 8\.Consent declined

Outcomes

Primary Outcomes

Not specified

Similar Trials